BG Medicine, Inc.  

(Public, NASDAQ:BGMD)   Watch this stock  
Find more results for BGMD
1.35
+0.16 (13.45%)
After Hours: 1.38 +0.03 (2.22%)
Apr 15, 7:57PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.16 - 1.39
52 week 0.55 - 2.42
Open 1.17
Vol / Avg. 0.00/2.67M
Mkt cap 46.43M
P/E     -
Div/yield     -
EPS -0.66
Shares 34.39M
Beta 2.98
Inst. own 37%
May 5, 2014
Q1 2014 BG Medicine Inc Earnings Release (Estimated) Add to calendar
Mar 20, 2014
Q4 2013 BG Medicine Inc Earnings Release
Mar 20, 2014
Q4 2013 BG Medicine Inc Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -355.83% -844.37%
Operating margin -326.50% -807.39%
EBITD margin - -797.69%
Return on average assets -92.22% -114.96%
Return on average equity -638.45% -224.23%
Employees 30 -
CDP Score - -

Address

SUITE 210, 880 WINTER STREET
WALTHAM, MA 02451
United States - Map
+1-781-8901199 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011, the Company entered into a supply agreement with Health Diagnostic Laboratory, Inc. (HDL), pursuant to which HDL agreed to purchase manual galectin-3 test kits from the Company and to offer galectin-3 testing services to physicians in the United States. This manual version of Its Galectin-3 test is being marketed in the United States through a number of regional and national laboratory testing facilities. In addition, it has partnered with four diagnostic instrument manufacturers, which are developing automated instrument versions of its galectin-3 test.

Officers and directors

Stephane Bancel Chairman of the Board
Age: 40
Bio & Compensation  - Reuters
Paul R. Sohmer M.D. President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Stephen P. Hall Chief Financial Officer, Executive Vice President
Age: 62
Bio & Compensation  - Reuters
Aram Adourian Ph.D. Senior Vice President, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Anastasia Rader Senior Vice President - Executive Operations & Human Resources
Age: 51
Bio & Compensation  - Reuters
Noubar B. Afeyan Ph.D. Independent Director
Bio & Compensation  - Reuters
Harrison M. Bains Jr. Independent Director
Age: 69
Bio & Compensation  - Reuters
Timothy Harris Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Stelios B. Papadopoulos Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Brian S. Posner Independent Director
Age: 51
Bio & Compensation  - Reuters